Saul is PharmSource’s Director of Market Intelligence. He brings over 15 years of experience in market analysis, having worked in business intelligence roles at Evaluate Pharma, Cardinal Health (now Catalent) and Abbott Laboratories. Prior to that, he was a Post-doctoral fellow in Neuropharmacology at the Universities of Birmingham and Bristol. Saul holds an MSc (Neuroscience) from the Institute of Psychiatry (King’s College London) and a D.Phil in Neuropharmacology from the University of Oxford.
Following two record fundraising years is a tough act, and 2016 is shaping up to be somewhat anti-climactic. The data in Figure 1 (below) demonstrates just how quickly the environment has changed since the heady days of 2015. CDMOs and CROs need to be concerned about what it implies for demand for their services. Venture […]
Contract service providers that specialize in “non-standard” dose forms can use the PharmSource Lead Sheet’s detailed dosage form options to zero-in on opportunities appropriate to their capabilities. The system offers over 30 different dosage form categories, enabling you to shine the spotlight exactly where it suits your needs. Here’s an example of just four of […]
The PharmSource Lead Sheet research team covered this year’s American Society of Clinical Oncology (ASCO) meeting in Chicago earlier this month. Our on-site attendance at events like this gets new information on clinical product updates to our clients days or even weeks earlier than other sources. We picked up new information on many next generation […]
The rise of biologics should be positive for the CMO sector. With the cost of a commercial large molecule manufacturing facility north of $200m, the rationale to outsource API manufacture to a third party could be viewed as compelling. Actual experience indicates that it isn’t any more compelling than for any other manufacturing activity. PharmSource […]
If you want to increase your success rate, double your failure rate. — Thomas Watson, Jr. In clinical trials, not all failures are equal. Late stage attrition is far more costly than drug candidate terminations occurring earlier in the development process. Among many other things, the PharmSource Lead Sheet provides coverage of products that have […]
In 2013, fully one third of approved New Molecular Entities (NMEs) were orphan drugs. Back in 1983, when Congress first established the orphan-drug designation, there was only one new such treatment per year across the industry; in the ensuing decades, that number has jumped to almost 200 per year. Today, nearly 33% of FDA-approved drugs […]